Roivant subsidiary Priovant reported that brepocitinib, a dual JAK1/TYK2 inhibitor licensed from Pfizer, met the primary goals of a proof-of-concept study in cutaneous sarcoidosis. The trial result positions the asset for pivotal testing in a rare inflammatory skin disorder that currently lacks FDA-approved therapies. The company said the data support moving toward larger, registrational studies; Priovant and Roivant will likely define the pivotal program and regulatory pathway next. The outcome matters because positive PoC in a rare, high-unmet-need indication can materially increase peak sales projections and shape licensing discussions.